RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @ATRIUMRx: As called for in this @JACCJournals expert consensus pathway, cardiology team members should be on the frontline of managing…
As called for in this @JACCJournals expert consensus pathway, cardiology team members should be on the frontline of managing DM to reduce CV risk, alongside primary care providers: https://t.co/i6sjrANy4y - @JJheart_doc #HFSA2019 https://t.co/2NwhedfM7d
Dr. Sandeep Das talking about 2018 ACC Expert Consensus Decision Pathway for CV risk reduction in patients with #T2D and atherosclerotic CV disease https://t.co/wQHbVcPFEY
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @icorvilud: #ADA2019 just published: Expert Consensus Pathway on CV risk reduction in #T2DMand #ASCVD https://t.co/wBoPm6B9iD https://t.…
RT @icorvilud: #ADA2019 just published: Expert Consensus Pathway on CV risk reduction in #T2DMand #ASCVD https://t.co/wBoPm6B9iD https://t.…
#ADA2019 just published: Expert Consensus Pathway on CV risk reduction in #T2DMand #ASCVD https://t.co/wBoPm6B9iD https://t.co/SsFsOKHG1v
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @cpcannon: Key new paradigm in DM management - treat the risk overall, with the right classes of meds (e.g. statins, ACE/ARB and SGLT2/G…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @cpcannon: Key new paradigm in DM management - treat the risk overall, with the right classes of meds (e.g. statins, ACE/ARB and SGLT2/G…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
https://t.co/gTLOzZOjV3 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease @ClubVasculaire @alebura @BozonGuillaume @LaurentBertole1 @G
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
Key new paradigm in DM management - treat the risk overall, with the right classes of meds (e.g. statins, ACE/ARB and SGLT2/GLPO-1RA) , and also get glycemic control
RT @JACCJournals: #ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus…
#ADA2019 is officially underway this weekend in San Francisco! Follow the link to revisit @ACCinTouch's Expert Consensus Pathway on CV risk reduction in Type 2 #Diabetes and #ASCVD released last fall in #JACC. https://t.co/77c4HnJhTr https://t.co/4DNkVtBvQ
RT @HeartOTXHeartMD: Expert Consensus Decision Pathway Addresses Changing Paradigm in Managing #T2D Patients With #ASCVD #Cardiologists 'U…
RT @IlindelatorreMD: Las guías de prevención primaria de la ACC sugieren que puede ser razonable (recomendación Clase IIb) que pacientes di…
RT @IlindelatorreMD: Las guías de prevención primaria de la ACC sugieren que puede ser razonable (recomendación Clase IIb) que pacientes di…
RT @HeartOTXHeartMD: Expert Consensus Decision Pathway Addresses Changing Paradigm in Managing #T2D Patients With #ASCVD #Cardiologists 'U…
RT @HeartOTXHeartMD: Expert Consensus Decision Pathway Addresses Changing Paradigm in Managing #T2D Patients With #ASCVD #Cardiologists 'U…
RT @HeartOTXHeartMD: Expert Consensus Decision Pathway Addresses Changing Paradigm in Managing #T2D Patients With #ASCVD #Cardiologists 'U…
Expert Consensus Decision Pathway Addresses Changing Paradigm in Managing #T2D Patients With #ASCVD #Cardiologists 'Uniquely Positioned' for Parts of #Diabetes Care #CardioDiabetology https://t.co/7LMT0xQAkI
RT @IlindelatorreMD: Las guías de prevención primaria de la ACC sugieren que puede ser razonable (recomendación Clase IIb) que pacientes di…
Las guías de prevención primaria de la ACC sugieren que puede ser razonable (recomendación Clase IIb) que pacientes diabéticos con enfermedad cardiovascular aterosclerótica establecida tomen iSGLT2 o agonistas del GLP para reducir eventos cardiovasculares.
RT @mencardio: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diab…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease | JACC: @ivanovich13 @torresviera @SIAC_cardio https://t.co/ICQwUpLR5u
@gmac78 I found this consensus document very helpful: https://t.co/YrOC8tRalg
What I think about SGLT2 inhibitors: The most important is to visualize the SGLT2 & NH1,3 pathway inside the heart failure approach. https://t.co/6gn3B8v8CD https://t.co/EW3Y6VQkk6
RT @DrRaniKhatib: In patients with cardiovascular disease with type 2 diabetes .. after lifestyle modification including healthy diet, weig…
RT @DrRaniKhatib: In patients with cardiovascular disease with type 2 diabetes .. after lifestyle modification including healthy diet, weig…
RT @DrRaniKhatib: In patients with cardiovascular disease with type 2 diabetes .. after lifestyle modification including healthy diet, weig…
In patients with cardiovascular disease with type 2 diabetes .. after lifestyle modification including healthy diet, weight loss and exercise...we should consider hypoglycaemics with potential CV benefit.
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @Medtorek: #SGLT2 inhibitors & #GLP-1, demonstrated that #treatments developed for glucose ⬇️ can directly improve #CV outcomes ❤️. Via…
RT @Medtorek: #SGLT2 inhibitors & #GLP-1, demonstrated that #treatments developed for glucose ⬇️ can directly improve #CV outcomes ❤️. Via…
RT @UREssien: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for ❤️ Risk Reduction in Patients With Type 2 Diabetes and Athe…
RT @Medtorek: #SGLT2 inhibitors & #GLP-1, demonstrated that #treatments developed for glucose ⬇️ can directly improve #CV outcomes ❤️. Via…
#SGLT2 inhibitors & #GLP-1, demonstrated that #treatments developed for glucose ⬇️ can directly improve #CV outcomes ❤️. Via @JACCJournals via @IlindelatorreMD @chemachir @vic_pallares #EPCCS @DrEvangel @javikin84 @VanessitaDeniz @SEMERGENap @wmarroc
RT @dianabrionesm98: Súper interesante artículo Dr https://t.co/GPuRj7oNZZ
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
Súper interesante artículo Dr
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
RT @IlindelatorreMD: El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto l…
El American College of Cardiology ha emitido un documento (Expert Consensus Decision Pathways) enfatizando que tanto los iSGLT2 como los agonistas GLP-1, deben onsiderarse no solo medicamentos antidiabéticos sino también agentes cardiovasculares. https://
RT @UREssien: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for ❤️ Risk Reduction in Patients With Type 2 Diabetes and Athe…
RT @UREssien: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for ❤️ Risk Reduction in Patients With Type 2 Diabetes and Athe…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for ❤️ Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic ❤️ Disease. Helpful framework from @JJheart_doc @sandeepdasmd @_brendan_ @willcefalu @JACCJournals and colleagues. ht
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @DrQuini: Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con DM II y EC…
Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con DM II y EC aterosclerótica https://t.co/ZaoEdsZ26b